These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1262787)

  • 21. Specificity of 2'-deoxycoformycin inhibition of adenosine metabolism in intact human skin fibroblasts.
    Holland MJ
    Res Commun Chem Pathol Pharmacol; 1986 Mar; 51(3):311-24. PubMed ID: 3486439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Animal model for immune dysfunction associated with adenosine deaminase deficiency.
    Tedde A; Balis ME; Ikehara S; Pahwa R; Good RA; Trotta PP
    Proc Natl Acad Sci U S A; 1980 Aug; 77(8):4899-903. PubMed ID: 6968908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of the biological activity of adenosine analogs by the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Adamson RH; Zaharevitz DW; Johns DG
    Pharmacology; 1977; 15(1):84-9. PubMed ID: 840892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2'-deoxycoformycin toxicity in murine spleen lymphocytes.
    Earle MF; Glazer RI
    Mol Pharmacol; 1983 Jan; 23(1):165-70. PubMed ID: 6602939
    [No Abstract]   [Full Text] [Related]  

  • 25. In vivo toxicity to lymphoid tissue by 2'-deoxycoformycin.
    Smyth JF; Young RC; Young DM
    Cancer Chemother Pharmacol; 1978; 1(1):49-51. PubMed ID: 750104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective immunotoxic effects in mice treated with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Luebke RW; Lawson LD; Rogers RR; Riddle MM; Rowe DG; Smialowicz RJ
    Immunopharmacology; 1987 Feb; 13(1):25-35. PubMed ID: 2952620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis of isocoformycin, an adenosine deaminase inhibitor of synthetic origin.
    Shimazaki M; Kondo S; Maeda K; Ohno M; Umezawa H
    J Antibiot (Tokyo); 1979 May; 32(5):537-8. PubMed ID: 528399
    [No Abstract]   [Full Text] [Related]  

  • 28. Adenosine and hypoxic vasodilatation.
    Dóra E
    J Cereb Blood Flow Metab; 1985 Dec; 5(4):621-4. PubMed ID: 3877069
    [No Abstract]   [Full Text] [Related]  

  • 29. Adenosine metabolism in phytohemagglutinin-stimulated human lymphocytes.
    Snyder FF; Mendelsohn J; Seegmiller JE
    J Clin Invest; 1976 Sep; 58(3):654-66. PubMed ID: 956393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Hershfield MS; Kurtzberg J; Harden E; Moore JO; Whang-Peng J; Haynes BF
    Proc Natl Acad Sci U S A; 1984 Jan; 81(1):253-7. PubMed ID: 6607471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolation of mutant adenosine deaminase by coformycin affinity chromatography.
    Danton MJ; Coleman MS
    Anal Biochem; 1986 Nov; 159(1):233-9. PubMed ID: 3492941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypnotic effects of deoxycorformycin in rats.
    Radulovacki M; Virus RM; Djuricic-Nedelson M; Green RD
    Brain Res; 1983 Jul; 271(2):392-5. PubMed ID: 6604561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of K and NK lymphocyte cytotoxicity by an inhibitor of adenosine deaminase and deoxyadenosine.
    Grever MR; Siaw MF; Coleman MS; Whisler RL; Balcerzak SP
    J Immunol; 1983 Jan; 130(1):365-9. PubMed ID: 6600187
    [No Abstract]   [Full Text] [Related]  

  • 34. Biochemical consequences of adenosine deaminase inhibition in vivo. Differential effects in acute and chronic T cell leukemia.
    Mitchell BS; Sidi Y; Hershfield M; Koller CA
    Ann N Y Acad Sci; 1985; 451():129-37. PubMed ID: 3878114
    [No Abstract]   [Full Text] [Related]  

  • 35. Transition-state stabilization by adenosine deaminase: structural studies of its inhibitory complex with deoxycoformycin.
    Frick L; Wolfenden R; Smal E; Baker DC
    Biochemistry; 1986 Apr; 25(7):1616-21. PubMed ID: 3486673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enzyme inhibition titration assay for 2'-deoxycoformycin and its application to the study of the relationship between drug concentration and tissue adenosine deaminase in dogs and rats.
    Chassin MM; Adamson RH; Zaharevitz DW; Johns DG
    Biochem Pharmacol; 1979 Jun; 28(12):1849-55. PubMed ID: 454456
    [No Abstract]   [Full Text] [Related]  

  • 37. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
    Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical and immunological evaluation of long term coformycin administration in the mouse.
    Lukey T; Snyder FF
    Adv Exp Med Biol; 1984; 165 Pt B():189-92. PubMed ID: 6720427
    [No Abstract]   [Full Text] [Related]  

  • 39. S-adenosylhomocysteine hydrolase activity, deoxyadenosine triphosphate accumulation, and competence of thymocyte and spleen leucocyte response to mitogens in coformycin-treated mice.
    Lukey T; Snyder FF
    Biochem Pharmacol; 1983 Apr; 32(8):1399-406. PubMed ID: 6860359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of lymphocyte function by 9-deazaadenosine.
    Zimmerman TP; Deeprose RD; Wolberg G; Stopford CR; Duncan GS; Miller WH; Miller RL; Lim MI; Ren WY; Klein RS
    Biochem Pharmacol; 1983 Apr; 32(7):1211-7. PubMed ID: 6303353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.